Quantum BioPharma Licensee Unbuzzd Wellness Inc. Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Quantum BioPharma (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has launched a $5 million Regulation D 506(c) capital raise to fund growth and prepare for a potential IPO. The company has engaged MZ Digital for marketing and Dealmaker as the crowdfunding platform.
Unbuzzd produces a scientifically-proven beverage that accelerates alcohol metabolism and reduces hangover symptoms. The company is led by CEO John Duffy, former Coca-Cola VP, and Board Co-Chair Gerry David, former CEO of Celsius Holdings. The funds will support direct-to-consumer, distributor, and retail expansion plans.
Quantum BioPharma (NASDAQ: QNTM) ha annunciato che la sua licenziataria, Unbuzzd Wellness Inc., ha avviato una raccolta fondi di 5 milioni di dollari tramite Regulation D 506(c) per finanziare la crescita e prepararsi a una possibile IPO. L'azienda ha ingaggiato MZ Digital per il marketing e Dealmaker come piattaforma di crowdfunding.
Unbuzzd produce una bevanda scientificamente comprovata che accelera il metabolismo dell'alcol e riduce i sintomi del post-sbornia. L'azienda è guidata dal CEO John Duffy, ex vicepresidente di Coca-Cola, e dal Co-presidente del consiglio Gerry David, ex CEO di Celsius Holdings. I fondi sosterranno i piani di espansione diretta al consumatore, distributori e vendita al dettaglio.
Quantum BioPharma (NASDAQ: QNTM) anunció que su licenciataria, Unbuzzd Wellness Inc., ha lanzado una recaudación de capital de 5 millones de dólares bajo la Regulación D 506(c) para financiar el crecimiento y prepararse para una posible oferta pública inicial (IPO). La compañía ha contratado a MZ Digital para marketing y a Dealmaker como plataforma de crowdfunding.
Unbuzzd produce una bebida científicamente comprobada que acelera el metabolismo del alcohol y reduce los síntomas de la resaca. La empresa está dirigida por el CEO John Duffy, ex vicepresidente de Coca-Cola, y el copresidente de la junta Gerry David, ex CEO de Celsius Holdings. Los fondos apoyarán los planes de expansión directa al consumidor, distribuidores y venta minorista.
Quantum BioPharma (NASDAQ: QNTM)는 라이선시인 Unbuzzd Wellness Inc.가 성장 자금 조달 및 잠재적 IPO 준비를 위해 Regulation D 506(c) 규정에 따른 500만 달러 자본 조달을 시작했다고 발표했습니다. 회사는 마케팅을 위해 MZ Digital을, 크라우드펀딩 플랫폼으로 Dealmaker를 선정했습니다.
Unbuzzd는 알코올 대사를 촉진하고 숙취 증상을 완화하는 과학적으로 입증된 음료를 생산합니다. 회사는 전 코카콜라 부사장인 CEO John Duffy와 전 Celsius Holdings CEO인 이사회 공동 의장 Gerry David가 이끌고 있습니다. 자금은 직접 소비자, 유통업체 및 소매 확장 계획을 지원하는 데 사용됩니다.
Quantum BioPharma (NASDAQ: QNTM) a annoncé que sa licenciée, Unbuzzd Wellness Inc., a lancé une levée de fonds de 5 millions de dollars via la Regulation D 506(c) pour financer sa croissance et préparer une éventuelle introduction en bourse. La société a fait appel à MZ Digital pour le marketing et à Dealmaker comme plateforme de crowdfunding.
Unbuzzd produit une boisson scientifiquement prouvée qui accélère le métabolisme de l'alcool et réduit les symptômes de la gueule de bois. La société est dirigée par le PDG John Duffy, ancien vice-président de Coca-Cola, et le coprésident du conseil d'administration Gerry David, ancien PDG de Celsius Holdings. Les fonds soutiendront les plans d'expansion directe aux consommateurs, distributeurs et détaillants.
Quantum BioPharma (NASDAQ: QNTM) gab bekannt, dass sein Lizenznehmer Unbuzzd Wellness Inc. eine 5-Millionen-Dollar-Kapitalerhöhung gemäß Regulation D 506(c) gestartet hat, um Wachstum zu finanzieren und sich auf einen möglichen Börsengang vorzubereiten. Das Unternehmen hat MZ Digital für das Marketing und Dealmaker als Crowdfunding-Plattform engagiert.
Unbuzzd stellt ein wissenschaftlich belegtes Getränk her, das den Alkoholstoffwechsel beschleunigt und Kater-Symptome reduziert. Das Unternehmen wird von CEO John Duffy, ehemaliger Vizepräsident von Coca-Cola, und dem Vorstandsvorsitzenden Gerry David, ehemaliger CEO von Celsius Holdings, geleitet. Die Mittel werden zur Unterstützung der Direktvertriebs-, Vertriebs- und Einzelhandelserweiterungspläne verwendet.
- Experienced leadership team includes former Coca-Cola VP and Celsius Holdings CEO
- Strategic partnership with leading marketing firm MZ Digital and crowdfunding platform Dealmaker
- Potential future IPO opportunity indicates growth trajectory
- No cap on capital raise amount under Regulation D 506(c)
- Dependence on successful completion of $5M capital raise for growth plans
- Limited to accredited investors only under Reg D 506(c)
- Early-stage company requiring significant capital for expansion
Insights
Quantum's licensee Unbuzzd launching $5M capital raise, potentially strengthening QNTM's portfolio value through future licensee growth.
The announcement that Quantum BioPharma's licensee Unbuzzd Wellness is pursuing a
The capital injection is strategically targeted to fuel Unbuzzd's multi-channel expansion across direct-to-consumer, distributor, and retail channels. The beverage company's focus on alcohol metabolism acceleration positions it in the functional beverage market, which has seen substantial growth in recent years.
What makes this particularly noteworthy is the leadership team behind Unbuzzd. CEO John Duffy brings over 20 years of beverage industry experience from executive roles at Coca-Cola, while Board Co-Chair Gerry David previously led Celsius Holdings during critical growth phases. This executive pedigree suggests implementation capability for the expansion strategy.
Most significantly for QNTM shareholders, the release explicitly mentions positioning Unbuzzd for a potential future IPO. As a licensee of Quantum BioPharma, any substantial growth or liquidity event for Unbuzzd would likely generate licensing revenue or other financial benefits for QNTM, depending on their specific agreement structure. The success of portfolio companies/licensees directly impacts the parent company's valuation multiples and revenue potential.
Engages leading marketing firm MZ Digital and crowdfunding platform Dealmaker to successfully execute raise
TORONTO, June 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™—the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms—is pleased to announce that it has engaged MZ Digital, a global leader in online marketing, and Dealmaker, a leading online platform for raising capital, to raise up to US
John Duffy, CEO of Unbuzzd Wellness Inc., stated, "We are dedicated to offering scientifically backed unbuzzd to alcohol consumers who want to enjoy themselves, stay in control, and feel great the next day. Our collaboration with MZ Digital and utilizing the Dealmaker platform will help us raise the necessary capital to support our direct-to-consumer, distributor, and retail expansion plans, allowing us to reach more consumers more often." Mr. Duffy has over twenty years of leadership experience in the beverage industry, including as former VP of Marketing Assets and VP of National Sales at Coca-Cola.
Gerry David, Board Co-Chair and former CEO of Celsius Holdings with their bestselling energy drink Celsius Energy, added, "This capital raise will give us the ability to continue to grow the company and expand sales, while positioning unbuzzd for a future initial public offering."
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans. Quantum BioPharma retains ownership of
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
About Unbuzzd Wellness Inc.
Unbuzzd Wellness inc., a non-trading but fully reporting public issuer, stands as a pioneering force in the wellness and recovery supplement landscape. unbuzzd has been developed by a world-class R&D team in pharmacology and medicine, with a commitment to innovation and quality. A proprietary blend of vitamins, minerals, and herbs, unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day.
Scientifically backed by a recently completed double-blind, randomized, placebo-controlled crossover design clinical trial, unbuzzd dramatically accelerates alcohol metabolism, speeds the reduction of blood alcohol concentration ("BAC"), restores mental clarity, and reduces the symptoms of intoxication, impairment and hangover. Key findings from the clinical trial include:
- Accelerated Alcohol Metabolism: unbuzzd dramatically and rapidly reduced blood alcohol concentration in study participants. The rate at which BAC was lowered was, on average for most participants, more than 40 percent faster within 30 minutes of consuming unbuzzd compared to control subjects. This faster reduction of BAC after consuming unbuzzd was both statistically significant compared to placebo and was observed at each subsequent measurement of BAC over a four-hour period.
- Rapid Improvements in Alertness: Study participants reported statistically significant improvement in alertness as soon as 30 minutes after consuming unbuzzd. Participants felt more alert and made fewer cognitive errors within 30 minutes of consuming unbuzzd, significantly outperforming placebo results.
- Rapid Improvements in Physiologic Changes due to Intoxication: unbuzzd lessened the elevation in heart rate and the drop in blood pressure that often accompanies alcohol intoxication, stabilizing both. This result was statistically significant.
- Reduced Perceived Impairment and Mental Fatigue: unbuzzd helped alleviate perceived impairment and mental fatigue caused by alcohol intoxication.
- Hangover Relief: Participants in this study noted a statistically significant reduction in hangover symptoms. This included reduced cognitive and physical impairment, and reduced headache compared to placebo results, at both four hours (67 percent reduction in headache severity) and eight hours after consuming unbuzzd.
- No Side Effects: unbuzzd was well-tolerated by all study participants, with no reported adverse side effects.
The full press release of the clinical trial can be found here.
unbuzzd ready-to-mix powder sticks are available in 3-pack and 18-pack formats at https://unbuzzd.com. unbuzzd is a registered trademark of Unbuzzd Wellness Inc.
Individual results may vary. unbuzzd is a dietary supplement. Consuming unbuzzd after alcohol ingestion does not permit you to operate a vehicle. Drink responsibly. DO NOT DRINK AND DRIVE.
For more information on Unbuzzd Wellness Inc. please visit www.unbuzzd.com
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
How much is Unbuzzd Wellness Inc. planning to raise through its Regulation D offering?
Who are the key executives leading Unbuzzd Wellness Inc.?
What will the capital raised be used for by Unbuzzd Wellness?
What is the relationship between Quantum BioPharma (NASDAQ: QNTM) and Unbuzzd Wellness?
Which firms are helping Unbuzzd Wellness with the capital raise?
